Compare IRWD & TSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRWD | TSAT |
|---|---|---|
| Founded | 1998 | 1969 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.6M | 697.5M |
| IPO Year | 2009 | 2021 |
| Metric | IRWD | TSAT |
|---|---|---|
| Price | $4.82 | $47.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | $7.67 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 1.8M | 196.2K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1400.00 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $298,276,000.00 | N/A |
| Revenue This Year | $57.95 | N/A |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | $31.07 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $0.55 | $15.36 |
| 52 Week High | $5.78 | $55.69 |
| Indicator | IRWD | TSAT |
|---|---|---|
| Relative Strength Index (RSI) | 67.86 | 58.31 |
| Support Level | $3.07 | $21.84 |
| Resistance Level | $5.67 | $55.69 |
| Average True Range (ATR) | 0.26 | 3.56 |
| MACD | 0.06 | -0.44 |
| Stochastic Oscillator | 94.83 | 46.34 |
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.